echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The opening action of 2020 pharmaceutical industry: a number of pharmaceutical enterprises merge and a number of pharmaceutical enterprises sell assets

    The opening action of 2020 pharmaceutical industry: a number of pharmaceutical enterprises merge and a number of pharmaceutical enterprises sell assets

    • Last Update: 2020-01-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [trends of pharmaceutical network industry] influenced by policies such as expanding with volume procurement, new medical insurance, consistency evaluation, etc., since the beginning of 2020, the actions of strategic adjustment of pharmaceutical enterprises are still relatively frequent Among them, a group of pharmaceutical companies merged, a group of pharmaceutical companies sold assets.. Some pharmaceutical people said: this year's start is very busy! On January 9, a number of pharmaceutical enterprises were merged Hubei Provincial Drug Administration announced that Hubei Xinye Pharmaceutical Co., Ltd was incorporated into Sinopharm holding Xinye (Hubei) Pharmaceutical Co., Ltd On October 10, Hubei Provincial Food and Drug Administration announced that Wuhan Qingda Yuanzhi Pharmaceutical Co., Ltd was incorporated into Wuhan BeiSen Pharmaceutical Co., Ltd Hubei Xinye Pharmaceutical Co., Ltd and Wuhan Qingda Yuanzhi Pharmaceutical Co., Ltd comply with the relevant regulations and requirements of the merger and reorganization of drug distribution enterprises in Hubei Province The drug regulatory bureau allows the two enterprises to apply for the cancellation of the "drug business license" and the "drug business quality management specification certificate" On January 10, Jiangsu Provincial Food and Drug Administration announced that Yangzhou Pharmaceutical was incorporated by Jiangsu Lianhuan pharmaceutical industry upon the written application of Yangzhou Pharmaceutical Co., Ltd Jiangsu Provincial Food and drug administration shall withdraw the drug production license of the company and cancel it Industry analysts said that the policy forced the industry to change, and small and medium-sized pharmaceutical enterprises could find new profit growth points through M & A and restructuring According to incomplete statistics in the industry, pharmaceutical companies have completed 39 asset sales in 2019 In addition, since December 2019, many well-known pharmaceutical enterprises, such as Haizheng pharmaceutical, Haier biology, humanwell pharmaceutical, Tianshili, Sihuan biology, Shuangcheng pharmaceutical, and foci pharmaceutical, have successively issued asset sale announcements On January 7, 2020, Haizheng pharmaceutical announced that its five apartments located in block a, Junyue building, Jiaojiang District, Taizhou City were successfully auctioned at a transaction price of RMB 1.82 million Haier biology also announced on January 6 that it would sell 75% of its stake in himI Kangji for 27 million yuan After the completion of the transaction, the company no longer has a business entity engaged in research and development, production and sales of molecular diagnosis POCT related products Industry analysts believe that due to the influence of policies such as volume purchasing and "two ticket system", pharmaceutical enterprises have been greatly impacted in recent years By reducing staff and reducing costs, increasing income from selling assets and other ways, the adjustment of marketing business and contraction of R & D pipeline may be to further activate assets, optimize resource allocation, focus on core business and control business risks For example, Tianshili said after selling Tianshi marketing that through the sale of the assets, the company will further focus on the pharmaceutical industry, continue to promote the coordinated development of modern Chinese medicine, biological medicine and chemical medicine, and build innovative pharmaceutical R & D clusters At the same time, the company plans to establish a long-term good cooperative relationship with Chongqing pharmaceutical in the pharmaceutical business field through this transaction, so as to achieve the strategic goal of win-win cooperation between the two sides Conclusion: in general, 2020 is a challenging year for pharmaceutical enterprises As early as the implementation of the generic drug consistency evaluation policy, some industry analysts have asserted that with the continuous promotion of the pharmaceutical policy, at least 3000 of China's more than 4000 pharmaceutical manufacturers will be eliminated in the future Under the attack of normalization of volume purchase, this process may accelerate to come, and it may be time for pharmaceutical enterprises to make corresponding decisions to adapt to the development.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.